Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 6, 2011, Pages 901-907

  Coppoletta, Stefania ^a   Tedone, Elisabetta ^a   Galano, Barbara ^a   Soracco, Monica ^a   Raiola, Anna Maria ^a   Lamparelli, Teresa ^a   Gualandi, Francesca ^a   Bregante, Stefania ^a   Ibatici, Adalberto ^a   di Grazia, Carmen ^a   Dominietto, Alida ^a   Varaldo, Riccardo ^a   Bruno, Barbara ^a   Frassoni, Francesco ^a   Van Lint, MariaTeresa ^a   Bacigalupo, Andrea ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Mabthera; PTLD; Unrelated transplants

Indexed keywords

RITUXIMAB; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; BLOOD DONOR; EPSTEIN BARR VIRUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; RISK FACTOR; SIDE EFFECT; VIRAL CLEARANCE; VIRUS LOAD;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTILYMPHOCYTE SERUM; BLOOD DONORS; DNA, VIRAL; DRUG DOSAGE CALCULATIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIREMIA; VIRUS ACTIVATION;

EID: 79956001828     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.003     Document Type: Article

References (27)

1. van Esser J.W., van der Holt B., Meijer E., et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001, 98:972-978.
2. Ocheni S., Kroeger N., Zabelina T., et al. EBV reactivation and post-transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008, 42:181-186.
3. Aalto S.M., Juvonen E., Tarkkanen J., et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007, 45:1305-1309.
4. Juvonen E., Aalto S.M., Tarkkanen J., et al. High incidence of PTLD after non-T cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003, 32:97-102.
5. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
6. Zutter M.M., Martin P.J., Sale G.E., et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988, 72:520-529.
7. Swinnen L.J., LeBlanc M., Grogan T.M., et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008, 86:215-222.
8. O'Reilly R.J., Lacerda J.F., Lucas K.G., et al. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. Important Adv Oncol 1996, 11:149-166.
9. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
10. Kuehnle I., Huls M.H., Liu Z., et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Blood 2000, 95:1502-1505.
11. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
12. van Esser J.W., Niesters H.G., van der Holt B., et al. Prevention of Epstein-Barr virus lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002, 99:4364-4369.
13. Powell J.L., Bunin N.J., Callahan C., et al. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004, 33:651-657.
14. Savoldo B., Rooney C.M., Quiros-Tejeira R.E., et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005, 5:566-572.
15. Ganne V., Siddiqi N., Kamaplath B., et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003, 17:417-422.
16. Blaes A.H., Peterson B.A., Bartlett N., et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005, 104:1661-1667.
17. Oertel S.H., Verschuuren E., Reinke P., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005, 5:2901-2906.
18. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107:3053-3057.
19. Dominietto A., Tedone E., Soracco M., et al. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplant based on molecular monitoring is predictive of lymphoproliferative disease. (abstract) Bone Marrow Transplant 2004, 33(Suppl 1). S192-S.
20. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day +7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391. Gruppo Italiano Trapianto Midollo Osseo (GITMO).
21. Corvò R., Lamparelli T., Bruno B., et al. Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT). Bone Marrow Transplant 2002, 30:717-723.
22. Raiola A.M., Van Lint M.T., Lamparelli T., et al. Reduced-intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000, 109:716-721.
23. Blaes A.H., Cao Q., Wagner J.E., et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:287-291.
24. Wagner H.-J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103:3979-3981.
25. Ahmad I., Cau N.V., Kwan J., et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem cell transplantation. Transplantation 2009, 87:1240-1245.
26. Zaia J., Baden L., Boeckh M.J., et al. Viral disease prevention after hemopoietic stem cell transplantation. Bone Marrow Transpl 2009, 44:471-482.
27. Heslop H.E. How I treat EBV lymphoproliferation. Blood 2009, 114:4002-4008.